Biogen (BIIB) EPS: History & Chart

Biogen Inc.(BIIB)

Drug Manufacturers - General · Cambridge, MA

$213.70-7.13 (-3.23%)

Delayed quote: Sep 8, 2026, 2:55 PM EDT

About Biogen Inc.

Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a selection of biosimilar drugs, including BENEPALI (an etanercept biosimilar akin to ENBREL), IMRALDI (an adalimumab biosimilar comparable to HUMIRA), and FLIXABI (an infliximab biosimilar referencing REMICADE). Further extending its therapeutic reach, Biogen supplies RITUXAN, prescribed for conditions like non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, certain types of ANCA-associated vasculitis, and pemphigus vulgaris. RITUXAN HYCELA targets non-Hodgkin's lymphoma and CLL, and GAZYVA is utilized for CLL and follicular lymphoma. OCREVUS addresses both relapsing and primary progressive forms of MS, complementing the company's broader efforts in anti-CD20 therapies. The company maintains a robust research and development pipeline, featuring numerous investigational therapies. These candidates are designed to tackle a wide spectrum of conditions, including multiple sclerosis and neuroimmunological disorders (e.g., BIIB135, BIIB061, BIIB091, BIIB107), Alzheimer's disease and other forms of dementia (e.g., Aducanumab, Lecanemab, BIIB076, BIIB080), neuromuscular disorders (e.g., BIIB067, BIIB078, BIIB105, BIIB100, BIIB110), Parkinson's disease and related movement disorders (e.g., BIIB124, BIIB094, BIIB118, BIIB101, BIIB122), neuropsychiatric conditions (e.g., BIIB125, BIIB104), immunology-related illnesses (e.g., Dapirolizumab pegol, BIIB059), acute neurological events (e.g., BIIB093, BIIB131), and neuropathic pain (e.g., BIIB074). Additionally, several biosimilar candidates, such as BYOOVIZ, BIIB800, and SB15, are progressing through various developmental stages. Biogen actively engages in strategic collaborations and licensing arrangements with various partners, including Acorda Therapeutics, Inc., Alkermes Pharma Ireland Limited, Denali Therapeutics Inc., Eisai Co., Ltd., Genentech, Inc., Neurimmune SubOne AG, Ionis Pharmaceuticals, Inc., Samsung Bioepis Co., Ltd., Sangamo Therapeutics, Inc., and Sage Therapeutics, Inc. Established in 1978, Biogen Inc. maintains its corporate headquarters in Cambridge, Massachusetts.

Cambridge, MA

7,500 employees

www.biogen.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Christopher A. Viehbacher

View full financials

BIIB Earnings Per Share (EPS) Metrics

EARNINGS PER SHARE (EPS)

5.65

EARNINGS PER SHARE (EPS) AVG TTM

10.02

EARNINGS PER SHARE (EPS) AVG 3Y

12.26

EARNINGS PER SHARE (EPS) AVG 5Y

14.06

EARNINGS PER SHARE (EPS) AVG 10Y

16.52

EARNINGS PER SHARE (EPS) AVG 15Y

13.55

EARNINGS PER SHARE (EPS) AVG 20Y

10.76

CURRENT VS TTM AVG

-43.64%

CURRENT VS 3Y AVG

-53.92%

CURRENT VS 5Y AVG

-59.81%

CURRENT VS 10Y AVG

-65.80%

CURRENT VS 15Y AVG

-58.31%

CURRENT VS 20Y AVG

-47.51%

NAME	MARKET CAP	EARNINGS PER SHARE (EPS)	TTM	3Y	5Y
Biogen Inc. (BIIB)	$31.58B	5.65	10.02	12.26	14.06
DexCom, Inc. (DXCM)vs ›	$32.07B	2.53	1.80	1.48	1.30
Zoetis Inc. (ZTS)vs ›	$31.05B	6.07	5.75	5.27	4.80
Centene Corp. (CNC)vs ›	$32.22B	-10.44	-3.64	-0.05	0.88
ResMed Inc. (RMD)vs ›	$32.19B	10.40	10.00	8.26	6.94
GE HealthCare Technologies Inc. (GEHC)vs ›	$30.35B	3.45	4.46	4.05	4.25
Waters Corporation (WAT)vs ›	$30.20B	4.01	10.78	11.05	10.65
Medline Inc. (MDLN)vs ›	$29.98B	0.86	1.48	0.80	0.80
Alcon Inc. (ALC)vs ›	$33.80B	1.30	2.02	1.68	1.07
Alnylam Pharmaceuticals, Inc. (ALNY)vs ›	$35.17B	5.92	0.10	-3.15	-4.54

NAME

MARKET CAP

EARNINGS PER SHARE (EPS)

TTM

Biogen Inc. (BIIB)

$31.58B

5.65

10.02

12.26

14.06

DexCom, Inc. (DXCM)vs ›

$32.07B

2.53

1.80

1.48

1.30

Zoetis Inc. (ZTS)vs ›

$31.05B

6.07

5.75

5.27

4.80

Centene Corp. (CNC)vs ›

$32.22B

-10.44

-3.64

-0.05

0.88

ResMed Inc. (RMD)vs ›

$32.19B

10.40

10.00

8.26

6.94

GE HealthCare Technologies Inc. (GEHC)vs ›

$30.35B

3.45

4.46

4.05

4.25

Waters Corporation (WAT)vs ›

$30.20B

4.01

10.78

11.05

10.65

Medline Inc. (MDLN)vs ›

$29.98B

0.86

1.48

0.80

Alcon Inc. (ALC)vs ›

$33.80B

1.30

2.02

1.68

1.07

Alnylam Pharmaceuticals, Inc. (ALNY)vs ›

$35.17B

5.92

0.10

-3.15

-4.54

Earnings Per Share (EPS) FAQ

What is the earnings per share (EPS) for Biogen Inc. (BIIB)?

The earnings per share (EPS) for BIIB stock is 5.65.

Is Biogen Inc.'s earnings per share (EPS) high or low?

The earnings per share (EPS) of 5.65 is 60% below its 5-year average of 14.06, near the low end of its 5-year range (5.65–24.86).

What is the TTM average earnings per share (EPS) for Biogen Inc. (BIIB)?

The TTM average earnings per share (EPS) for BIIB stock is 10.02.

What is the 3Y average earnings per share (EPS) for Biogen Inc. (BIIB)?

The 3Y average earnings per share (EPS) for BIIB stock is 12.26.

What is the 5Y average earnings per share (EPS) for Biogen Inc. (BIIB)?

The 5Y average earnings per share (EPS) for BIIB stock is 14.06.

What is the 10Y average earnings per share (EPS) for Biogen Inc. (BIIB)?

The 10Y average earnings per share (EPS) for BIIB stock is 16.52.

What is the 15Y average earnings per share (EPS) for Biogen Inc. (BIIB)?

The 15Y average earnings per share (EPS) for BIIB stock is 13.55.

What is the 20Y average earnings per share (EPS) for Biogen Inc. (BIIB)?

The 20Y average earnings per share (EPS) for BIIB stock is 10.76.

DATE	EARNINGS PER SHARE (EPS)
2025-12-31	8.85
2024-12-31	11.20
2023-12-31	8.02
2022-12-31	20.97
2021-12-31	10.44
2020-12-31	24.86
2019-12-31	31.47
2018-12-31	21.62
2017-12-31	11.94
2016-12-31	16.96
2015-12-31	15.38
2014-12-31	12.42
2013-12-31	7.86
2012-12-31	5.80
2011-12-31	5.09
2010-12-31	3.98
2009-12-31	3.37
2008-12-31	2.67
2007-12-31	2.02
2006-12-31	0.64
2005-12-31	0.48
2004-12-31	0.07
2003-12-31	-2.62
2002-12-31	0.51
2001-12-31	0.70
2000-12-31	0.75
1999-12-31	0.49
1998-12-31	0.16
1997-12-31	0.10
1996-12-31	0.05

DATE

EARNINGS PER SHARE (EPS)

2025-12-31

8.85

2024-12-31

11.20

2023-12-31

8.02

2022-12-31

20.97

2021-12-31

10.44

2020-12-31

24.86

2019-12-31

31.47

2018-12-31

21.62

2017-12-31

11.94

2016-12-31

16.96

2015-12-31

15.38

2014-12-31

12.42

2013-12-31

7.86

2012-12-31

5.80

2011-12-31

5.09

2010-12-31

3.98

2009-12-31

3.37

2008-12-31

2.67

2007-12-31

2.02

2006-12-31

0.64

2005-12-31

0.48

2004-12-31

0.07

2003-12-31

-2.62

2002-12-31

0.51

2001-12-31

0.70

2000-12-31

0.75

1999-12-31

0.49

1998-12-31

0.16

1997-12-31

0.10

1996-12-31

0.05

Earnings Per Share (EPS): 5.65

BIIB Earnings Per Share (EPS)

BIIB Quarterly EPS Growth (YoY)

BIIB P/E Ratio

BIIB P/E Ratio Chart

BIIB Average Earnings Per Share (EPS) Chart

BIIB Current vs Average Earnings Per Share (EPS) Chart

BIIB Earnings Per Share (EPS) Metrics

BIIB Competitors' Earnings Per Share (EPS)

EPS Comparison

Earnings Per Share (EPS) Formula & Definition

Earnings Per Share (EPS) FAQ

BIIB Earnings Per Share (EPS) History

Related Metrics

BIIB PEG Ratio

BIIB PEG Ratio Chart